2026 Volume: 01 Issue: 07 ISSN 1671-2838 Page No: 329-340

Pharmaceutical Care and Research

https://pcrjournal.com

Review Article

Volume: 01
Issue: 07

A DETAILED REVIEW ON A SIGNAL DETECTION IN PHARMACOVIGILANCE

Tanvi Sayaji Mane,[1] Dr. Prasad V. Patrekar[2], Saurabh D. Joshi[3*], Poonam A. Mane- Patil[4]

[1]Student, [2]Principal, [3]Assistant Professor, [4]Assistant Professor.

Eklavya College of Pharmacy, Tasgaon, Maharashtra, India.

Article Received: 23 August 2026

Article Revised: 11 September 2026

Published on: 01 October 2026

***Corresponding Author: Saurabh D. Joshi**

Assistant Professor, Eklavya College of Pharmacy, Tasgaon, Maharashtra, India.

DOI: https://doi-doi.org/101555/ijpcr.6539

ABSTRACT

Pharmacovigilance plays an important role in patient safety through a process of detecting analysing interpreting, and disseminating information about adverse effects of drugs after licensure. Although safety data from clinical trials are the first lines of evidence that is crucial still limitations like small sample size, relatively homogeneous patient pool, short duration of exposure, highly restricted study environment etc. are often pointed out as reasons why rare, delayed or actual-world adverse drug reactions are being missed. That's why, monitoring of the marketed medicines has been recognized as one of the main ways through which a number of new safety signals and the balance between benefit and risk are determined. Considering Really spontaneous reports mostly from health professionals and patients still constitute the mainstay for pharmacovigilance, the recognition of infrequent (very rare), uncommon delayed and drug-drug interactions etc. which are quite a challenge for spontaneous reports may need large scale data collection. The availability of individual case safety (ICS) reports will provide an opportunity for pharmacovigilance to be a bit more organized at least and for having a more systematic way to identify safety signals in a timely manner. The use of signal detection methods such as the Bayesian Confidence Propagation Neural Network (BCPNN) and the Reporting Odds Ratio (ROR) have demonstrated usefulness in the identification of false-positives and/or spurious drug event associations. The advent of large-scale databases, implementation of electronic health records, the adoption of data-quality practices and mechanisms for duplication of reporting, data-mining programs, new statistical techniques are all aspects surrounding complex machine learning which appear to be great means for getting a hold on how quick and how precisely safety concerns are recognized. In this way, combining classical approaches alongside newly developed ones could be an effective way of elevating the clinical value and efficiency of pharmacovigilance operations, health care system, clinicians reliance on the scientifically valid evidence, and citizens' trust in the medical field.

KEYWORDS: Pharmacovigilance, Adverse Drug Reactions, Drug Safety, Signal Detection, Post-Marketing Surveillance, Drug Safety Signals, Signaling regulations.

INTRODUCTION

All drugs are related to adverse effect and whenever a drug is given in practice a risk is taking. For deciding whether or not to prescribe particular drug for particular patient its risks must be compared with benefits. Lazarou et al. 1998 suggested adverse drug reactions (ADRs) are four to six recommmonest causes of death. Further 6.5% to 6.89% of all the in hospital population are admitted into hospital for drug related adverse effect, which prolong their stay in hospital and this way adds to their treatment cost to the patient in 2007. It is predicted that more than 50% of the ADRs is definitely or possibly preventable. During drug research (Phase 1-Phase 3), ADRs reported to the regulatory authorities and ethical committees are filed as drug safety update reports (DSURs). Any ADR reported during the trails, Principal Investigators report to sponsor within 24hrs and to Institutional review board within 14 working days and sponsor report it to the regulatory authorities within 14 calendar days. There are few problems in adopting this process in all the in the survey of all the population, (I) homogenous population sample (strict inclusion/exclusion criteria, volunteers with single disease, specific groups of children, old aged and pregnant women being excluded), (ii) small sample number (detection of rare adverse reactions appears to be dose problem), (iii) short duration of individual trail (limits the detection of long term adverse reactions), (iv) unable to detect ADRs under real term conditions (drug interaction, food interaction), there is an immediate requirement of system which keeps an eye on the ADRs of pharmaceutical products. Pharmacovigilance is just in phase 4 of the drug development process or post marketing surveillance. World Health organization (WHO) defines Pharmacovigilance as a science about the collection detection assessment, monitoring and prevention of adverse effects from medicines or any other drug related problems. The main aim of pharmacovigilance is to quantitate already known adverse effect, to find out the unknown effect and to test the power of drugs in real life situation, and to reduce the death and environment morbidity. [1]

Clinical trials undertaken pre-launch have had too few patients, too few groups of them, in too artificial settings to define the whole "antipattern" of a new medicine's possible adverse reactions, so post-market surveillance is needed. Detecting a new safety problem can have a huge impact on a medicine benefit risk profile; for example, rofecoxib has been withdrawn after the possible increased risk of myocardial infarction was demonstrated. Individual case reports of presumed drug induced damage will always be the main method for uncovering new or unforeseen safety concerns connected to medicines. Its greatest strength is the new insights obtained from the vigilant eyes and ears of patients and doctors to inform causality assessment; also it covers all medicines and patient groups in a single system. Its main weaknesses are that not all suspected ADRs are identified as such, that not all suspected ADRs are reported, and that the information reported is sometimes insufficient to draw definitive causality conclusions. Several large projects are currently investigating longitudal health

data for its utility in safety signal detection, and seems like this approach can be used along side, but not instead of individual case reports. A practical issue when searching individual case reports for new risks posed by medicines is that the volume of cases is very high. For many organizations, the absolute number of submitted reports and the number of potential drug ADR combinations offers too much information to search thoroughly; approaches for prioritizing case review are so required.1 level of evidence, newness, and impact on healthcare resources [1]. Since the 1990s computerized assessment of level of evidence has been predominantly performed using the technique called disproportionality analysis; due to its usability in practice, it has grown from an obscure technique to an everyday analytical method in the last 15 years. But, this brings a very primitive association analysis only, examining the statistical co-reporting of drugs and symptoms in a dataset. It is based solely on the pooled report numbers, it ignores individual report details, and assumes simple independence and co-report counts. More sophisticated techniques with more complex analysis resulted in the development of multivariate methods which take into account the knowledge of other co-reported drugs and indication. These offer potentially less confounded measures of strength of association, but they have not yet shown their superiority for pharmacovigilance. At the same time, these multivariate techniques analyze only a few aspects of information within each individual report apart from its drugs and symptoms, and occasional indication. Automated systems for detecting at unusual time to onset patterns study has a different aspect of strength of association, but are just one more source of information to consider. [2]

1.1 Sources of Drug Information

SmPC is a legal document that describes the usage of a medicine in the UK and eMC stores SmPCs. FDA labeling of drugs listed in Drugs@FDA or DailyMed is the FDA counterpart of SmPC. The primary sources to check whether an adverse drug-drug interaction (DDI) is an 'approved drug-drug adverse event' as described in the regulatory documents (labelling) are: drug's product information (SmPC) from eMC, FDA drug's label from either Drugs@FDA or DailyMed. ADrugDex interactions and Janusmed Interactions drug interactions were used as the secondary references if the information was not present at the other sources. [3]

The reason we decided on this approach was a result of a very large dataset of 123 initial cases we had collected in a phase of a drug identification that we carried on as a first phase drug identification. At case identification we were a starting point in the identification of case using a set of signals and by utilizing two original MedDRA preferred terms (PTs) "wrong technique in product use" and "Drug administered in wrong device" these two preferred terms were actually the ones that allowed me to narrow down the search to the identification of cases. In fact, from these initial stories that allowed the identification of 117 cases, the core elements behind the making of the errors in EIPPCS have already been identified which will include the errors made as users were handling the device itself, a device

being wrongly introduced or the patients are the ones at fault about making the deliberate mistakes in how the devices are being used..[4]

The data results were based on a specific database version of VigiBase, which is an authoritative global safety case report database of individuals compiled by the World Health Organization. It was the first week of February 2018 before the version change and up to that moment there were 16 036 530 records in the database after suspected duplicate cases, reports from other countries (i.e. in which the country of occurrence does not match the country of reporting), had been removed. Products which VigiBase identifies solely as suspected or interacting with other products were the subject of the assessment. [5]

It is hoped that the present study will be able to greatly raise the issue of the new drug-ADR combination patterns that are only starting to appear in the real-world clinical scenarios because of this it might give rise to some drug safety signals also, inculcate the concept of pharmacovigilance, and make the healthcare professionals realize the importance of pharmacovigilance. If associations between a drug and a harmful event are spotted at an early stage, this will result in a new safety signal. There is an overwhelming call for the clinical research study to be carried out immediately to find potential adverse consequences, signals for these and related findings, and data that support evidence-based clinical medicine. The pharmacovigilance of the future must meet the clinical requirements of young people for drugs that are safe, enhance the health services, lower health costs, as well as strengthen consumer confidence in health systems. [6]

1.2 Signal Generation

The two disproportionality methods applied in this paper was the Reporting odds ratio (ROR) and the Bayesian Confidence Propagation Neural Network. The first one is widely used by the European Medicine Agency. The second one is developed and maintained by Uppsala Monitoring Center as one of the systems of WHO. When talking about the ROR approach a safety disproportionality report (SDR) is considered as the true drug-drug interaction (DII) only if the lower confidence bound of ROR (RORLB) > 1 and the number of observed drug-event pairs >3; for the Bayesian method a signal is considered when the lower bound of the IC 95% confidence interval > 0.[7]




Fig. (1). Different sources of generation of safety signals. [8]

Healthcare professionals always try to find the best way to detect and quantify adverse drug effects among inpatients. The drug expert, the clinical pharmacist, is the one who is able to catch early signs of adverse drug reactions and also drug-related problems. The clinical pharmacist is further involved in the use of computer systems to monitor medicines efficacy and, at the same time, drug use. A combination of medication errors and relative risk of side effects from medication. Besides case-control studies there are cohort studies that are employed for the safety evaluation safety issues in specific populations such as the elderly children women patients, pregnant women.[9]

1.3 Pharmacovigilance And Signal Detection

The WHO global database for medicines and vaccines measures commissioned Post Marketing Surveillance reporting of ADRs from WHO member states pharmacovigilance centres reporting to the WHO Programme for International Drug Monitoring. Reporting of ADRs are subject to standardised processes before inclusion in the database. The database involves 36 individual countries, of which an analysis is performed for specific geographical regions like all data within the UN Asia area between 2016 to 2021. The continual harmonisation of reports between reporting centres is maintained through regular updates and robust quality control measures. The EudraVigilance database is the pharmacovigilance infrastructure of the European Economic Area, providing standardisation of reports of suspected ADRs of all licensed medicines within member states. Serious and nonserious

reported ADRs across marketing authorisation until the reporting time are included in a centralized database. Representative analyses include the determination of opioid safety profiles in Germany and a longitudinal assessment of the safety of fosfomycin from initial licensing until October 2021. The EU-ADR Web Platform is an analytical data-sharing platform which helps identify signals of drug adverse event associations by distributed analytics of longitudinal EHRs obtained from multiple participating European nations in a near real-time data analysis model while working in tandem with spontaneous reporting systems. Examples include the detection timeliness and accuracy improvement analysis of integrated spontaneous reporting systems and EHRs, and cost efficiency analysis according to event type and data set access. DATA PREPARATION AND QUALITY CONTROL Pathogen isospectral matching executed through the VigiMatch algorithm recognises suspected duplicate records. Probabilities are produced based on fields matched and information entry anomalies. Validation studies show that positive prediction values range from 86% in the UK to 33% in Spain, with many false positives being cases of related drugs. VigiMatch has also identified suspected duplicate reports which passed previous rules-based duplicate detection algorithms. Evaluation studies in 2025 show newer algorithms much improve upon VigiMatch for precision, recall, and false reporting rates. Denominator estimated metrics are an important aspect for work reporting like the PRR. A cross organisation combined systematized standardisation system such as the ATC/DDD (Anatomical Therapeutic Chemical / Defined Daily Dose) corrects differences in prescribing behaviour, including drug exposure calculations in DDDs/1000 inhabitants/day based on successive elements of the prescription (N) Dosage (M), pack size (Q) associated WHO DDD value(1), population size(P), interval.[10]

Signal detection depends highly on solid statistical ways. The most widely implemented disproportionality measures, i.e. Information Component (IC), PRR, and Reporting Odds Ratio (ROR) - continue to be used with great popularity while machine learning-based approaches are emerging to either supplement or replace them in many situations, providing better sensitivity, specificity, and timeliness. [11]

A Hybrid system that includes pharmacological network. Modelling together with implementation of a Bayesian method showed an enhanced result and AUC of 0.8291 versus IC (0.7343), ROR (0.6828), and PRR (0.6721)[12]

Still, the spontaneous reporting systems have been created and implemented all over the globe. The quantity of complaints of adverse drug reaction that is brought to the attention of the World Health Organization (WHO-UMC) collaborating Centre for International Drug Monitoring in Uppsala, Sweden keeps increasing and the figure has now reached about 2 00 000 annually.[13]

Despite the advancements, signal detection of medication errors remains a challenge, since many of these terms do not have the required level of detail to identify the fundamental cause of the error. A main reason for Really medication errors are a consequence of a series of incidents that have been influenced by human behaviour and thinking. For this reason, pharmacovigilance professionals have

to rely on describing the signal as part of the narrative inorder to carry out their analysis. Because of this, such a procedure proves to be both a lengthy and labourious task. In addition, since the task involves hand checking, it is also hampered by in reality there are more reports of medication errors submitted than ever before. [14]

Drug interactions may occur when several drugs share the same target proteins, as well as pharmacological and metabolic pathways which may change the safety and/or efficacy of pharmaceutical products. Put it another way, the combined administration, may result in significant changes from the drug agent's efficacy and/or safety profiles. Unexpected drug-drug interactions (DDIs) are generally identified only through signal detection practices and the postmarketing life cycle. [15]

Pharmacovigilance deals with drug safety where adverse reactions reports are collected processed assessed and interpreted for understanding the risks tied to drug/biologic therapy. Detecting signals refers to analyzing adverse events patterns through a process of identifying a possible link between a drug and a side effect. The occurrence of a signal should cause further investigation of the issue. The event causing the signal could be one that was not previously known or it could be a well recorded event that the patient population at risk for the event is not yet identified. It can also be a signal that the number and/or severity of the events are higher than expected. Signal generation is the result of either a qualitative analysis of spontaneous reports or of quantitative analysis performed with the help of data mining and statistical evaluation. [16]

1.4 Data Extraction

In a number of studies on signal detection based on supervised Machine Learning (ML) models, we have determined: the source(s) of the database(s) used to provide training/testing samples, the number of product-event combinations (PECs) available from that database, kind of events (the signals, the clinical concepts targeted by the study) and, last but not least, types of drugs included in each PEC (not simply \"all\" or \"any\" drug belonging to a drug dataset). We also specified the number of positive/negative control PECs used in each training dataset as well as the methods (applied/adopted), the performance indicators resulting from those methods, and finally the outcomes of the feature analyses. In those cases where negative and positive control data from reference were extracted from multiple sources or in case of multiple test sets, the most favorable performance level is presented without averaging since imputation has been neither carried out, neither implied. Different aspects have been addressed for feature selection, including but not limited to relevance discrimination frequency, correlation. [17]

Signal handling is made up of various signal tasks, namely signal detection validation prioritizing, and assessing the risk, (i.e. synonymously termed hereinafter as "assessment"). At the end, according to the result of the assessment, the proper recommendations for risk mitigation and patient safety

assurance are given, which may involve changes in labeling of newly identified drug side effects (ADRs).[18]

1.5 Data Collection and Processing

For this study, a case-non-case analysis was conducted with help of a national pharmacovigilance database. All actual adverse events (AEs) reports in Antbacterials for systemic use (ATC J01) that reported in the KID-Kd were posted during 10-year (January 2009 to December 2018). The research was waived by the institutional review board of the Ewha Woman's University because the research type and use of the information were not of medical research. They include 'patient info', 'drug data', 'detail of AE', 'serious of AE', 'reporter information', 'causality assessor', and 'patients history'. The medicines were classified as the ATC codes only. PTs from WHO-ART (WHO Adverse Reaction Terminology) 092 were used for coding the data about AE related information. All the serious AE like dead or life threatening disabling birth defects disability require or prolong hospital, and other medically important AE were considered as dangerous AE. All the information including the drug name and the ATC code was given from KIDS data controller as well as presented in the download file that researcher can download as much as like from KID Kd. Completeness of data was checked by identify the input or logical errors of data. The duplicates were omitted and only the first presentation for one case was concerned (not analyze the follow-up reports). The reports causality assessed as 'likely' or then were taken for analysis. Only the reports which occurred pain after completion of surgery, prescriber's mistake of drugs, and medical device complication were excluded. There were some cases which contain several drugs and multiple AE. Finally, the data of only single drug one AE sets were used. [19]

1.6 Signaling regulations and guidelines

The main idea behind quantifying the benefits/risk ratio is a simple calculation that divides the number to benefit by the number to be harmed.31 The FDA has created a qualitative table/grid through which it can pinpoint major factors for benefits - risks balancing when it comes to biopharma products. The Medical Device Innovation Consortium collaborates very intimately with the Center for Devices and Radiological Health(CDRH) on the Patient Centered Benefit, Risk Project. [20]

According to FDA's Good Pharmacovigilance Practices guidance, the way of detecting and explaining safety signals with case reports, case series cohort case-control or nested case-control studies, registries, and surveys is outlined.2 Besides this, it gives recommendations about the interpretation of signals. Requirements for signal detection are implied but not clearly stated in the FDA Amendment Act, although they are fully explained in the guidance.

CIOMS VIII: Practical Aspects of Signal Detection in Pharmacovigilance[21]

FDA Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment

European Medicines Agency (EMA) Guideline on Good Pharmacovigilance Practice (GVP) Module IX: Signal Management.[22]

Instructions provided on over-the-counter medicines are also written in common language. These instructions encourage safe and proper usage of medicines. In the US, the FDA lays down the rules about patient leaflets, and from time to time, it brings out amendments to already approved patient package inserts.

The Centre for Innovation in Regulatory Science (CIRS) has two initiatives in the process of being carried out."Unified approaches for Benefit-Risk assessment" was conceived as the means of a common platform upon which benefit-risk ways can be coordinated for international use.[23]

The ICH guideline M4E, "Common", was published in March 2004. It was in the new format, where the generic information was written beyond the industry section.

Was revised02 in the technical document "applying for registration of medicines for human use - Efficacy" ICH M4E(r2) guideline has been established to provide consistency in presenting benefit and risk data in regulatory submissions and recommendations. The revised ICH M4E(r2) guideline Defines a structure for the Common Technical Tools&document (CTD) in Section 2.5.6, Benefits and. Risk Conclusions. This part of the CTD . Should reflect the line of deliberation leading to the the applicant's for balancing costs and risks. Present a concise and evaluative presentation to the group.[24]

The SPC is not meant to provide general advice on the treatment of a condition.It rather clearly outlines the manner and purpose of the use of the product for a particular disease. In addition, a product's SPC serves Health Professionals' reference about how a product can be used safely and effectively. Also, the leaflet which comes with the product is more exactly targeting the ultimate users.[25]

CONCLUSION

Pharmacovigilance is a key aspect of drug safety management since adverse reactions may not be caught during pre-marketing clinical trials that are often constrained by a small number of subjects, a narrow range of age groups and diseases, very short follow-up periods, or highly rigid study environments. In fact, ongoing post-marketing surveillance is a very powerful means of discovering both previously unknown new and those unexpected adverse drug reactions as well as reassessing safety benefit-risk ratios of drugs. It is of course true that single safety reports submitted individually still provide useful information for identification of new drug safety problems, but at-risk (RoB), relative risk (RR), and Bayesian Confidence Propagation Neural Networks (BCPNN) method plus other proportionality-based disproportionality methods can also detect potential safety signals through a more structured approach. The increased availability of databases that provide huge amounts of data for pharmacovigilance and patient health electronically-recorded data has made it possible to use more advanced methods for signal detection. Procedures that ensure correctness of data including data standardization or normalization, identification of duplicates, data quality and consistency checks, and

the application of different machine learning models enable us to better and speedier analyze a batch of drug-event reports and give them different levels of priority Yet, keep in mind that even if a safety signal is indicated with statistics or a machine that makes such a detection automatically does not mean it is definitely a real drug safety problem. The alarm of such an automated detection must be understood as the initiation and the first basis in a process of evaluation by a human medical and epidemiologic mind. To sum up, integrating spontaneous drug-safety reporting systems with the traditional approach of disproportionality analysis, employing up-to-the-standard clinical data, and the latest computer-assisted techniques could bring better monitoring of drug safety and earlier identification of potential drug problems. Effective pharmacovigilance not only safeguards a drug, but it also prevents patients from harm, reduces the cost for a medical system, and improves the level of trust by the public and medical professionals.

REFERENCES

1. Kumar A, Khan H. Signal detection and their assessment in pharmacovigilance. Open Pharmaceutical Sciences Journal. 2015 Dec 17; 2(1).
2. Caster O, Juhlin K, Watson S, Norén GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank: retrospective evaluation against emerging safety signals. Drug safety. 2014 Aug; 37(8):617-28.
3. Hult S, Sartori D, Bergvall T, Hedfors Vidlin S, Grundmark B, Ellenius J, Norén GN. A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance: S. Hult et al. Drug safety. 2020 Aug; 43(8):775-85.
4. Eskildsen NK, Eriksson R, Christensen SB, Aghassipour TS, Bygsø MJ, Brunak S, Hansen SL. Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors. BMC Medical Informatics and Decision Making. 2020 May 24; 20(1):94.
5. Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations: O. Caster et al. Drug safety. 2020 May; 43(5):479-87.
6. Devi M. A Review on Signal in Pharmacovigilance. Asian Journal of Pharmaceutical research and development. 2019 Jan 1.
7. Khouri C, Nguyen T, Revol B, Lepelley M, Pariente A, Roustit M, Cracowski JL. Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances. Frontiers in pharmacology. 2021 May 28; 12:668765.
8. Raine JM, Ed. Risk management a European regulatory view. In: Mann R, Andrews E. Pharmacovigilance. Chichester: Wiley 2007.
9. Shayna G. Clinical Trials Handbook. USA: John Wiley 2009.

10. Mugada V, Suryadevara V, Cheekurumilli M, Yarguntla SR. Signal detection in pharmacovigilance: Methods, tools, and workflows from case identification to adverse drug reaction database entry. Przegląd Epidemiologiczny-Epidemiological Review. 2025 Dec 12; 79(3):404-14.
11. Shen J, Lin A, Cheng Q, Zhang J, Luo P. Abstract 6380: Exploring immune checkpoint inhibitorrelated adverse events in pediatric cancer patients: A pharmacovigilance analysis of VigiBase and the FDA adverse event reporting system (FAERS) database. Cancer Res. 2024; 84(6_Suppl):6380. http://dx.doi.org/10.1158/1538-7445.AM2024- 6380.
12. Ji X, Cui G, Xu C, Hou J, Zhang Y, Ren Y. Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events. Front Pharmacol. 2022; 12:773135. http://dx.doi. org/10.3389/fphar.2021.773135
13. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16: 355-65.
14. Newbould V, Meur S, Goedecke T, Kurz X. Medication errors: a characterisation of spontaneously reported cases in EudraVigilance. Drug Saf. 2017; 40(12):1241–8.
15. Norén G, Sundberg R, Bate A. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008; 27:3057–3070.
16. IOMS. Practical aspects of signal detection in pharmacovigilance. *Report of CIOMS Working Group VIII*, https://cioms.ch/working_groups/working-group-viii/ (2008).
17. Warner J, Prada Jardim A, Albera C. Artificial Intelligence: Applications in Pharmacovigilance Signal Management: J. Warner et al. Pharmaceutical Medicine. 2025 May; 39(3):183-98.
18. Ball R, Dal Pan G. "Artificial intelligence" for pharmacovigilance: ready for prime time? Drug Saf. 2022; 45(5):429–38.
19. Choi JY, Choi JH, Kim MG, Rhie SJ. Signal detection of adverse drug reactions of cephalosporins using data from a national pharmacovigilance database. Pharmaceuticals. 2021 May 2;14(5):
20. MDIC. Medical Device Innovation Consortium (MDIC) patient centered benefit–riskrisk project report, http://mdic.org/wp-content/ uploads/2015/05/MDIC_PCBR_Framework_ Proof5_Web.pdf (2015).
21. Nathan JP and Vider E. The package insert. US Pharm 2015; 40: 8–10.
22. Malikova MA. Practical applications of regulatory requirements for signal detection and communications in pharmacovigilance. Therapeutic advances in drug safety. 2020 April; 11:2042098620909614.
23. Bujar M, McAuslane N, Salek S, et al. CIRS R&D briefing 61: Building quality into decisionmaking processes in medicines' development, Regulatory Review and Health Technology Assessment. Centre for Innovation in Regulatory Science, http://www.cirsci.org/wp-content/ uploads/2017/01/CIRS-RD-Briefing-61- Decision-making.pdf (2017).

24. Revision of M4E guideline on enhancing the format and structure of benefit-risk information in ICH, https://www.ema.europa.eu/en/documents/ scientific-guideline/ich-m4e-r2-commontechnical-document-registration-pharmaceuticalshuman-use-efficacy-step-5_en.pdf (2016).
25. European Medicines Agency. Marketing authorisation - Product-information requirements, https://www.fda.gov/files/drugs/published/Format-and-Content-of-a-REMSDocument-Guidance-for-Industry.pdf (2019).